Sofinnova Partners sells its stake in Corvidia in $2.1bn deal
Life sciences venture capital firm Sofinnova Partners has sold its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1bn.
Life sciences venture capital firm Sofinnova Partners has sold its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1bn.
Recent Comments